US 11254669
Fused imidazo-piperidine JAK inhibitors
granted A61KA61K31/437A61P
Quick answer
US patent 11254669 (Fused imidazo-piperidine JAK inhibitors) held by Theravance Biopharma R&D IP, LLC expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K31/437, A61P, A61P11/00, A61P11/06